Avadel Pharmaceuticals (AVDL) Stock Forecast & Price Target

Q: What is AVDL’s average 12-month price target, according to analysts?

Based on analyst ratings, Avadel Pharmaceuticals’s 12-month average price target is 20.86.

Q: What is AVDL’s upside potential, based on the analysts’ average price target?

Avadel Pharmaceuticals has 35.45% upside potential, based on the analysts’ average price target.

Q: Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

Q: How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Q: Is AVDL a Buy, Sell or Hold?

Avadel Pharmaceuticals has a consensus rating of Strong Buy which is based on 8 buy ratings, 1 hold ratings and 0 sell ratings.

Q: What is Avadel Pharmaceuticals’s price target?

The average price target for Avadel Pharmaceuticals is 20.86. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $36.00 ,the lowest forecast is $16.00. The average price target represents 35.45% Increase from the current price of $15.4.

Q: What do analysts say about Avadel Pharmaceuticals?

Avadel Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.

Q: How can I buy shares of AVDL?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Compare

769 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

AVDL Analyst Ratings

Strong Buy

8 Buy

1 Hold

0 Sell

Based on 9 analysts giving stock ratings to

Avadel

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

AVDL Stock 12 Month Forecast

Average Price Target

$20.86

▲(35.45% Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Avadel Pharmaceuticals in the last 3 months. The average price target is $20.86 with a high forecast of $36.00 and a low forecast of $16.00. The average price target represents a 35.45% change from the last price of $15.40.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","37":"$37","13.75":"$13.75","21.5":"$21.5","29.25":"$29.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":36,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$36.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20.86,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$20.86</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$16.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,13.75,21.5,29.25,37],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.98,16.596923076923076,18.213846153846156,19.83076923076923,21.447692307692307,23.064615384615387,24.681538461538462,26.298461538461538,27.915384615384617,29.532307692307693,31.14923076923077,32.76615384615384,34.38307692307693,{"y":36,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.98,15.432307692307692,15.884615384615385,16.336923076923078,16.78923076923077,17.24153846153846,17.693846153846152,18.146153846153847,18.59846153846154,19.05076923076923,19.50307692307692,19.955384615384617,20.407692307692308,{"y":20.86,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.98,15.05846153846154,15.136923076923077,15.215384615384616,15.293846153846154,15.372307692307693,15.45076923076923,15.52923076923077,15.607692307692307,15.686153846153847,15.764615384615384,15.843076923076923,15.92153846153846,{"y":16,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.17,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.16,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.05,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.59,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.51,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.9,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.91,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.51,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.61,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.49,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.81,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.08,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.98,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$36.00

Average Price Target$20.86

Lowest Price Target$16.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Ram Selvaraju

H.C. Wainwright

$24→$36

Buy

133.77%

Upside

Reiterated

09/05/25

Avadel Pharmaceuticals price target lowered to $36 from $246 at H.C. WainwrightAvadel Pharmaceuticals price target lowered to $36 from $246 at H.C. Wainwright

David Amsellem

Piper Sandler

$16

Buy

3.90%

Upside

Reiterated

09/05/25

Piper Sandler Reaffirms Their Buy Rating on Avadel Pharmaceuticals (AVDL)

Chase Knickerbocker

Craig-Hallum

―

Buy

―

Reiterated

09/04/25

Craig-Hallum Keeps Their Buy Rating on Avadel Pharmaceuticals (AVDL)

Marc Goodman

Leerink Partners

―

Buy

―

Reiterated

09/04/25

Avadel Pharmaceuticals: Positioned for Growth with Lumryz and Strategic AcquisitionsWe don’t disagree that low sodium is important for narcolepsy patients with cardiovascular comorbidities, but our understanding is that that population represents <20% of these patients. With that said, Jazz has done a great job playing defense. However, the launch of a product that is both once nightly and low sodium would nullify that advantage and could be the go-to oxybate product of choice. Jazz is also working on this type of product but has kept very quiet about its program, so it’s difficult to know whether it’s having formulation issues or just remaining quiet for competitive reasons. Either way, we think this deal is a good move for Avadel.

Bryce Generon

TR | OpenAI - 4o

$15→$16.5

Buy

7.14%

Upside

Upgraded

09/04/25

AI Generated ArticleAI Generated Article

Francois Brisebois

LifeSci Capital

$20→$21

Buy

36.36%

Upside

Reiterated

09/04/25

Avadel Pharmaceuticals: Strong Sales Growth and Strategic Positioning Drive Buy Rating

Benjamin Burnett

Wells Fargo

$16

Hold

3.90%

Upside

Initiated

09/03/25

Avadel Pharmaceuticals initiated with an Equal Weight at Wells FargoAvadel Pharmaceuticals initiated with an Equal Weight at Wells Fargo

Ashwani Verma

UBS

$13→$20

Buy

29.87%

Upside

Reiterated

08/21/25

Avadel Pharmaceuticals price target raised to $20 from $13 at UBSAvadel Pharmaceuticals price target raised to $20 from $13 at UBS

David Hoang

Deutsche Bank

$16→$18

Buy

16.88%

Upside

Reiterated

08/08/25

Avadel Pharmaceuticals price target raised to $18 from $16 at Deutsche BankAvadel Pharmaceuticals price target raised to $18 from $16 at Deutsche Bank

Ami Fadia

Needham

$22→$19

Buy

23.38%

Upside

Reiterated

08/07/25

Needham Keeps Their Buy Rating on Avadel Pharmaceuticals (AVDL)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Ram Selvaraju

H.C. Wainwright

$24→$36

Buy

133.77%

Upside

Reiterated

09/05/25

Avadel Pharmaceuticals price target lowered to $36 from $246 at H.C. WainwrightAvadel Pharmaceuticals price target lowered to $36 from $246 at H.C. Wainwright

David Amsellem

Piper Sandler

$16

Buy

3.90%

Upside

Reiterated

09/05/25

Piper Sandler Reaffirms Their Buy Rating on Avadel Pharmaceuticals (AVDL)

Chase Knickerbocker

Craig-Hallum

―

Buy

―

Reiterated

09/04/25

Craig-Hallum Keeps Their Buy Rating on Avadel Pharmaceuticals (AVDL)

Marc Goodman

Leerink Partners

―

Buy

―

Reiterated

09/04/25

Bryce Generon

TR | OpenAI - 4o

$15→$16.5

Buy

7.14%

Upside

Upgraded

09/04/25

AI Generated ArticleAI Generated Article

Francois Brisebois

LifeSci Capital

$20→$21

Buy

36.36%

Upside

Reiterated

09/04/25

Avadel Pharmaceuticals: Strong Sales Growth and Strategic Positioning Drive Buy Rating

Benjamin Burnett

Wells Fargo

$16

Hold

3.90%

Upside

Initiated

09/03/25

Avadel Pharmaceuticals initiated with an Equal Weight at Wells FargoAvadel Pharmaceuticals initiated with an Equal Weight at Wells Fargo

Ashwani Verma

UBS

$13→$20

Buy

29.87%

Upside

Reiterated

08/21/25

Avadel Pharmaceuticals price target raised to $20 from $13 at UBSAvadel Pharmaceuticals price target raised to $20 from $13 at UBS

David Hoang

Deutsche Bank

$16→$18

Buy

16.88%

Upside

Reiterated

08/08/25

Avadel Pharmaceuticals price target raised to $18 from $16 at Deutsche BankAvadel Pharmaceuticals price target raised to $18 from $16 at Deutsche Bank

Ami Fadia

Needham

$22→$19

Buy

23.38%

Upside

Reiterated

08/07/25

Needham Keeps Their Buy Rating on Avadel Pharmaceuticals (AVDL)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Avadel Pharmaceuticals

1 Month

xxx

Success Rate

11/20 ratings generated profit

Average Return

+6.90%

reiterated a xxx

rating 11 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 55.00% of your transactions generating a profit, with an average return of +6.90% per trade.

3 Months

xxx

Success Rate

17/28 ratings generated profit

Average Return

+11.61%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 60.71% of your transactions generating a profit, with an average return of +11.61% per trade.

1 Year

Chase KnickerbockerCraig-Hallum

Success Rate

15/20 ratings generated profit

Average Return

+34.26%

reiterated a buy rating 11 days ago

Copying Chase Knickerbocker's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +34.26% per trade.

2 Years

xxx

Success Rate

19/25 ratings generated profit

Average Return

+82.84%

reiterated a xxx

rating 11 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 76.00% of your transactions generating a profit, with an average return of +82.84% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AVDL Analyst Recommendation Trends

Rating

May 25

Jun 25

Jul 25

Aug 25

Sep 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, AVDL has received 15 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. AVDL average Analyst price target in the past 3 months is 20.86.

Each month's total comprises the sum of three months' worth of ratings.

AVDL Financial Forecast

AVDL Earnings Forecast

Next quarter’s earnings estimate for AVDL is $0.07 with a range of $0.03 to $0.16. The previous quarter’s EPS was $0.10. AVDL beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.16% of the time in the same period. In the last calendar year AVDL has Outperformed its overall industry.

AVDL Sales Forecast

Next quarter’s sales forecast for AVDL is $73.58M with a range of $72.52M to $74.70M. The previous quarter’s sales results were $68.13M. AVDL beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.14% of the time in the same period. In the last calendar year AVDL has Outperformed its overall industry.

AVDL Stock Forecast FAQ

What is AVDL’s average 12-month price target, according to analysts?

Based on analyst ratings, Avadel Pharmaceuticals’s 12-month average price target is 20.86.

What is AVDL’s upside potential, based on the analysts’ average price target?

Avadel Pharmaceuticals has 35.45% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is AVDL a Buy, Sell or Hold?

Avadel Pharmaceuticals has a consensus rating of Strong Buy which is based on 8 buy ratings, 1 hold ratings and 0 sell ratings.

What is Avadel Pharmaceuticals’s price target?

The average price target for Avadel Pharmaceuticals is 20.86. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $36.00 ,the lowest forecast is $16.00. The average price target represents 35.45% Increase from the current price of $15.4.

What do analysts say about Avadel Pharmaceuticals?

Avadel Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of AVDL?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Avadel Pharmaceuticals (AVDL) Stock Forecast & Price Target

AVDL Analyst Ratings

AVDL Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Avadel Pharmaceuticals

AVDL Analyst Recommendation Trends

AVDL Financial Forecast

AVDL Earnings Forecast

AVDL Sales Forecast

AVDL Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts